Prudential Financial Inc Macrogenics Inc Transaction History

Prudential Financial Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$9.77 - $21.47 $317,525 - $697,775	-32,500 Reduced 60.73%	21,015 $309,000
Q4 2023 Feb 13, 2024	SELL	$4.48 - $10.11 $52,147 - $117,680	-11,640 Reduced 17.87%	53,515 $514,000
Q3 2023 Nov 13, 2023	SELL	$4.48 - $6.19 $51,520 - $71,185	-11,500 Reduced 15.0%	65,155 $303,000
Q2 2023 Aug 11, 2023	SELL	$4.62 - $7.54 $249,249 - $406,783	-53,950 Reduced 41.31%	76,655 $410,000
Q1 2023 May 12, 2023	SELL	$4.82 - $7.24 $585,148 - $878,936	-121,400 Reduced 48.17%	130,605 $936,000
Q4 2022 Feb 14, 2023	BUY	$3.34 - $6.98 $457,580 - $956,260	137,000 Added 119.13%	252,005 $0
Q3 2022 Nov 04, 2022	BUY	$3.01 - $5.22 $346,165 - $600,326	115,005 New	115,005 $398,000
Q1 2022 May 13, 2022	SELL	$8.12 - $16.9 $140,516 - $292,454	-17,305 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$15.91 - $21.88 $2.03 Million - $2.79 Million	-127,583 Reduced 88.06%	17,305 $278,000
Q1 2019 May 15, 2019	BUY	$11.11 - $25.6 $764,923 - $1.76 Million	68,850 Added 90.55%	144,888 $0
Q4 2018 Feb 07, 2019	BUY	$11.75 - $21.42 $893,446 - $1.63 Million	76,038 New	76,038 $965,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Prudential Financial Inc with notifications on news.